Citius Oncology annual shareholders’ equity
2021
2022
2022
2023
2023
2024
2025
Citius Oncology Shareholders’ Equity Growth & History (CTOR)
Citius Oncology's shareholders’ equity was $44.9M for fiscal 2025.
View full Citius Oncology company overviewCitius Oncology annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $44.9M | −$1.3M | −2.76% |
| 2024 | 2024-09-30 | $46.1M | $20.6M | +80.69% |
| 2023 · Dec 31 | 2023-12-31 | $22.7M | $22.4M | +6477.35% |
| 2023 · Sep 30 | 2023-09-30 | $25.5M | −$10.7M | −29.59% |
| 2022 | 2022-12-31 | $345,508 | $355,621 | — |
| 2022 | 2022-09-30 | $36.3M | — | — |
| 2021 | 2021-12-31 | −$10,113 | — | — |
Citius Oncology quarterly shareholders’ equity
Q4.21
Q3.22
Q4.22
Q1.23
Q2.23
Q4.23
Q4.23
Q1.24
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $40.4M | $8.0M | +24.65% |
| Q2 2026 | 2026-03-31 | $35.3M | −$373,863 | −1.05% |
| Q1 2026 | 2025-12-31 | $58.4M | $17.1M | +41.47% |
| Q4 2025 | 2025-09-30 | $44.9M | −$1.3M | −2.76% |
| Q3 2025 | 2025-06-30 | $32.4M | $15.4M | +90.23% |
| Q2 2025 | 2025-03-31 | $35.6M | $15.8M | +79.59% |
| Q1 2025 | 2024-12-31 | $41.3M | $18.6M | +81.69% |
| Q4 2024 | 2024-09-30 | $46.1M | $20.6M | +80.69% |
| Q2 2024 | 2024-06-30 | $17.0M | $17.0M | — |
| Q1 2024 | 2024-03-31 | $19.8M | $19.6M | +9944.59% |
| Q4 2023 · Dec 31 | 2023-12-31 | $22.7M | $22.4M | +6477.35% |
| Q4 2023 · Sep 30 | 2023-09-30 | $25.5M | $25.5M | — |
| Q2 2023 | 2023-06-30 | −$1,968 | — | — |
| Q1 2023 | 2023-03-31 | $197,586 | — | — |
| Q4 2022 | 2022-12-31 | $345,508 | $355,621 | — |
| Q3 2022 | 2022-09-30 | −$10,113 | — | — |
| Q4 2021 | 2021-12-31 | −$10,113 | — | — |
Citius Oncology shareholders’ equity trends
Between the periods ended 2021-12-31 and 2025-09-30, Citius Oncology's shareholders’ equity increased from −$10,113 to $44.9M, a change of $44.9M. The latest reported quarter, Q3 2026, shows $40.4M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Citius Oncology source filings ↗Community posts
Citius Oncology’s wholesaler shipments rise sharply while institutional orders grow modestly
Citius Oncology ($CTOR) reported preliminary sales of 792 Lymphir units to US wholesalers for its fiscal fourth quarter of 2026, up 120% from 360 in the preceding quarter. Separately, prescribing centers ordered 950 vials from wholesalers, ...
